Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Barbara Eichhorst, EHA 2022: What did the GAIA/CLL13 study teach us about the impact of venetoclax and obinutuzumab in fit patients with CLL?

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 18th 2022

Prof Barbara Eichhorst (University Hospital Cologne, Cologne, Germany) discusses the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy.

The abstract ‘TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL’ (Abstract: LB2365) was presented at the EHA2022 Congress, 9-12 June 2022.

Questions

  1. What has been the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy? (00:20-00:58)
  2. What did the GAIA/CLL13 study teach us about the impact of venetoclax and obinutuzumab in fit patients with CLL? (00:58-01:42)
  3. What were the objectives of the current analysis? (01:42-02:18)
  4. What were the findings in terms of progression-free survival? (02:18-03:27)
  5. What will be the impact of these findings on the treatment paradigm for CLL? (01:27-04:31)

Disclosures: Barbara Eichhorst is a consultant for: Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche and Sandoz. She has received grant/research support from: Biogen, Research Fund Flanders, Charcot Foundation Belgium, Merck, Sanofi-Genzyme and Roche. She is on the advisory board for: Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche and Sandoz.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 27th Congress of the European Hematology Association (EHA)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup